UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) Nevada 99-0931141 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission file number: 00 ...

Exhibit 99.1 Callan JMB Announces Second Quarter 2025 Financial Results and Provides Business Update Appointed Christopher Shields, former Assistant Commissioner of the Chicago Department of Public Health, as Senior Vice President, Emergency Preparedness & Response/Government Af airs Supported Texas and New Mexico with measles outbreak response through redistribution of MMR II vaccines SPRING BRANCH, Texas, August 14, 2025 — Callan JMB INC. (NASDAQ: CJMB) ("Callan JMB" or the "Company"), an integrative logi ...

Core Viewpoint - Callan JMB Inc. has made significant strides in expanding its logistics services for the healthcare sector, including forming strategic partnerships, launching international operations, and enhancing emergency preparedness capabilities, positioning itself for sustained growth in high-demand markets [2][3]. Business Highlights - A strategic partnership was formed with Revival Health Inc. to create an integrated supply chain infrastructure for health, wellness, and longevity products, enhancing distribution capabilities [2][3]. - The company launched a subsidiary in India, establishing a temperature-controlled warehouse in Pune for pharmaceutical storage and distribution, and has secured agreements with local companies to facilitate U.S. market entry [2][3]. - Callan JMB extended its emergency preparedness contract with the City of Chicago through June 2026, increasing total contract value to $9.1 million with an additional $1.5 million in funding [2][3]. - Christopher Shields was appointed as Senior Vice President for Emergency Preparedness & Response/Government Affairs to expand operations into new markets [2][3]. - The company successfully redistributed over 1,300 MMR II vaccine doses during a measles outbreak response, demonstrating its logistical efficiency and sustainability [2][3]. Financial Highlights - For the three months ended June 30, 2025, revenues were $1.7 million, a decrease from $2.0 million in the same period last year, attributed to reduced demand for emergency preparedness services [8][10]. - Gross profit for the same period was $0.6 million, down from $1.0 million year-over-year [8][11]. - Selling, general, and administrative expenses increased to $2.0 million for the quarter, primarily due to costs associated with being a public entity and new senior staff hires [8][11]. - The net loss for the three months ended June 30, 2025, was $1.4 million, compared to a loss of $0.1 million in the prior year [8][11]. - Cash and cash equivalents as of June 30, 2025, were $4.2 million, an increase from $2.1 million at the end of the previous year [8][13].

Core Insights - Callan JMB INC. has been awarded a six-month extension to its pallet storage contract with the City of Chicago, increasing the total contract value to $9.1 million with an additional funding of $1.5 million [1][2][3] Group 1: Contract Details - The contract extension allows Callan JMB to continue managing and distributing stored emergency supplies for the City of Chicago until June 20, 2026 [2] - The partnership has been in place since 2018, highlighting a long-term relationship between Callan JMB and the City of Chicago [1][2] Group 2: Company Performance and Commitment - The CEO of Callan JMB expressed pride in the extension, indicating it reflects the company's operational excellence and the trust placed in them by the City of Chicago [3] - The company emphasizes its commitment to providing exceptional service and supporting emergency response needs in the community [3] Group 3: Company Overview - Callan JMB is described as an integrative logistics company that supports the healthcare industry and emergency management through various services, including fulfillment, storage, and cold chain logistics [4] - The company claims to have unparalleled expertise in supply chain logistics, regulatory compliance, and emergency preparedness, aiming to secure medical materials and protect public health [4]

Core Insights - Callan JMB has established a subsidiary in India, Callan JMB Services (India) Private Limited, to provide logistics services for pharmaceuticals, including a warehouse in Pune for temperature-sensitive storage and distribution [1][2] - The subsidiary aims to assist Indian companies in setting up manufacturing plants in the U.S. and has already secured agreements with Walker's Pharmaceuticals Ltd. and Brihans Natural Products Ltd. for distribution and manufacturing support [2][3] - The company emphasizes its expertise in cold chain logistics, which is crucial for importing tissue samples and active pharmaceutical ingredients (APIs) from India to the U.S., addressing drug shortages and facilitating clinical trials [3] Company Overview - Callan JMB is an integrative logistics company focused on empowering the healthcare sector through services such as fulfillment, storage, monitoring, and cold chain logistics, ensuring compliance and safety in medical material distribution [4] - The company combines expertise in supply chain logistics, thermodynamics, biologics, inventory management, and regulatory compliance, positioning itself as a leader in the industry [4]

Core Insights - Callan JMB redistributed over 1,300 doses of the MMR II vaccine from Chicago to Texas and New Mexico to combat measles outbreaks, ensuring no vaccines were wasted [1][2] - The company utilized specialized cold chain reusable shippers with active temperature monitoring to maintain required temperatures during transit, and all shippers were recovered and recertified for reuse [3][4] - The operation exemplified effective collaboration between public health departments across states to ensure critical medications reach communities during outbreak responses [4] Company Overview - Callan JMB Inc. is an integrative logistics company that supports the healthcare industry and emergency management agencies through services such as fulfillment, storage, monitoring, and cold chain logistics [5] - The company emphasizes its expertise in supply chain logistics, thermodynamics, biologics, inventory management, regulatory compliance, and emergency preparedness, aiming to provide a gold standard in client experience and environmental sustainability [5]

Core Insights - Callan JMB Inc. will participate in Maxim Group's 2025 Virtual Tech Conference from June 3-5, 2025, highlighting its role in the healthcare logistics sector [1][2] Company Overview - Callan JMB Inc. is an integrative logistics company focused on empowering the healthcare industry and emergency management agencies through services such as fulfillment, storage, monitoring, and cold chain logistics [3] - The company aims to secure medical materials and protect patients and communities by providing compliant, safe, and effective medicines [3] - Callan JMB boasts unparalleled expertise in supply chain logistics, thermodynamics, biologics, inventory management, regulatory compliance, and emergency preparedness [3] - The company emphasizes a gold standard in client experience, offering customizable interfaces and reliable shipping with a focus on environmental sustainability in specialty packaging [3]

Core Insights - The formation of a joint venture between Callan JMB and Revival Health aims to integrate logistics, shipping systems, bioservices, and data infrastructure to enhance the importation and U.S.-based manufacturing of health and wellness products [1][2] - This collaboration seeks to create a next-generation supply chain that combines Callan JMB's logistics expertise with Revival Health's consumer-focused approach to preventive care [2][3] Company Overview - Callan JMB is an integrative logistics company that provides fulfillment, storage, monitoring, and cold chain logistics services to the healthcare industry and emergency management agencies [4] - Revival Health focuses on delivering timely preventive care at scale through an integrated platform that includes diagnostics, telemedicine, and personalized healthcare solutions [5] Strategic Goals - The joint venture aims to build a comprehensive supply platform that fundamentally changes the availability of healthcare products in the U.S. [3] - The collaboration is designed to meet the growing demand for scalable and compliant distribution of health and wellness products [2][3] Operational Capabilities - Callan JMB's Coldchain Technology Services will provide end-to-end support, including transportation, warehousing, quality assurance, data integration, and regulatory compliance [3] - The joint venture is positioned to enhance the accessibility of preventive care tools for consumers [4]

PART I - FINANCIAL INFORMATION [Item 1. Unaudited Financial Statements](index=3&type=section&id=Item%201.%20Unaudited%20Financial%20Statements) Unaudited Q1 2025 financials show asset growth post-IPO, a 19% revenue decline, and increased net loss from public company costs [Condensed Consolidated Balance Sheets](index=4&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) As of March 31, 2025, total assets increased to **$8,455,666** and stockholders' equity to **$6,807,581**, driven by IPO proceeds and cash growth Condensed Consolidated Balance Sheet Highlights | Metric | March 31, 2025 | December 31, 2024 | | :--- | :--- | :--- | | **Assets** | | | | Cash | $5,219,929 | $2,097,945 | | Total Current Assets | $6,802,104 | $3,319,188 | | Total Assets | $8,455,666 | $5,082,549 | | **Liabilities & Equity** | | | | Total Current Liabilities | $1,048,896 | $1,274,315 | | Total Liabilities | $1,648,085 | $1,909,191 | | Total Stockholders' Equity | $6,807,581 | $3,173,358 | [Condensed Consolidated Statements of Operations](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) Q1 2025 revenue decreased **19%** to **$1,449,377**, while a **130%** surge in SG&A led to a **$1,240,590** net loss Q1 2025 vs. Q1 2024 Performance | Metric | Three months ended March 31, 2025 | Three months ended March 31, 2024 | | :--- | :--- | :--- | | Revenue | $1,449,377 | $1,790,521 | | Gross Profit | $615,940 | $717,583 | | Operating Loss | $(1,238,376) | $(87,459) | | Net Loss | $(1,240,590) | $(81,133) | | Net Loss per Share | $(0.32) | $(0.03) | [Condensed Consolidated Statement of Stockholders' Equity](index=6&type=section&id=Condensed%20Consolidated%20Statement%20of%20Stockholders%27%20Equity) Stockholders' equity increased to **$6,807,581** by March 31, 2025, driven by **$4.54 million** IPO proceeds, offset by a **$1,240,590** net loss - The company issued **1,280,000** shares in its IPO and an additional **163,569** shares for the over-allotment option, raising a total of **$4.54 million** net of costs[16](index=16&type=chunk) - The net loss for the quarter was **$1,240,590**, which reduced retained earnings (accumulated deficit)[16](index=16&type=chunk) [Condensed Consolidated Statement of Cash Flows](index=7&type=section&id=Condensed%20Consolidated%20Statement%20of%20Cash%20Flows) Q1 2025 cash increased by **$3,121,984**, with **$1,561,698** used in operations and **$4,698,682** provided by IPO financing activities Cash Flow Summary (Q1 2025 vs. Q1 2024) | Cash Flow Activity | For the three months ended March 31, 2025 | For the three months ended March 31, 2024 | | :--- | :--- | :--- | | Net cash (used in) operating activities | $(1,561,698) | $6,839 | | Net cash used in investing activities | $(15,000) | $(44,656) | | Net cash from (used in) financing activities | $4,698,682 | $(3,460,286) | | **Increase (decrease) in cash** | **$3,121,984** | **$(3,498,103)** | - The company received **$4,680,013** in net proceeds from its IPO and over-allotment during the quarter[20](index=20&type=chunk) [Notes to Condensed Consolidated Financial Statements](index=8&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) Notes detail reorganization, **$4.7 million** IPO proceeds, **56%** customer concentration, a **$240,800** legal settlement, and new lease agreements - The company was formed on January 24, 2024, to become a holding company for Coldchain Technology Services, LLC, its main operating subsidiary[21](index=21&type=chunk) - The company has significant customer concentration, with one customer representing **56%** of revenue in Q1 2025 and another representing **14%**[40](index=40&type=chunk) - In February 2025, the company completed its IPO, generating gross proceeds of approximately **$5.776 million** and net proceeds of approximately **$4.7 million**[68](index=68&type=chunk) - A legal matter with a vendor was settled in February 2025 for **$240,800**[80](index=80&type=chunk) - Subsequent to quarter end, on April 1, 2025, the company entered into two new leases: a five-year warehouse lease and a ten-year corporate office lease[82](index=82&type=chunk)[83](index=83&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=22&type=section&id=Item%202.%20MANAGEMENT%20DISCUSSION%20AND%20ANALYSIS%20OF%20FINANCIAL%20AND%20RESULTS%20OF%20OPERATIONS) Management attributes Q1 2025 revenue decline to lower demand, with increased operating expenses and net loss from IPO and public company costs [Results of Operations](index=23&type=section&id=Results%20of%20Operations) Q1 2025 revenue fell **19%** to **$1,449,377** due to lower demand, while SG&A surged **130%**, leading to a **$1,238,376** operating loss Q1 2025 vs. Q1 2024 Operational Results | Metric | 2025 | 2024 | Change | Change % | | :--- | :--- | :--- | :--- | :--- | | Revenue | $1,449,377 | $1,790,521 | $(341,144) | -19% | | Gross Profit | $615,940 | $717,583 | $(101,643) | -14% | | SG&A Expenses | $1,854,316 | $805,042 | $1,049,274 | 130% | | Income (loss) from operations | $(1,238,376) | $(87,459) | $(1,150,917) | 1316% | | Net income (loss) | $(1,240,590) | $(81,133) | $(1,159,457) | 1429% | - The decrease in revenue was due to the diminution in demand for our emergency preparedness services by certain states and local governments[94](index=94&type=chunk) - The increase in SG&A expenses was driven by higher personnel costs (**$100,795**), professional fees for the IPO (**$212,677**), marketing and investor relations (**$189,707**), and stock-based compensation (**$330,825**)[97](index=97&type=chunk) [Liquidity and Capital Resources](index=24&type=section&id=Liquidity%20and%20Capital%20Resources) Liquidity strengthened with cash reaching **$5,219,929** due to **$4.7 million** IPO proceeds, despite **$1,561,698** cash used in operations - As of March 31, 2025, the company had **$5,219,929** in cash and cash equivalents[99](index=99&type=chunk) Cash Flow Changes (Q1 2025 vs. Q1 2024) | Cash Flow Activity | For Three Months Ended March 31, 2025 | For Three Months Ended March 31, 2024 | | :--- | :--- | :--- | | Cash (used in) operating activities | $(1,561,698) | $6,839 | | Cash (used in) investing activities | $(15,000) | $(44,656) | | Cash from (used in) financing activities | $4,698,682 | $(3,460,286) | - The increase in cash from financing activities was primarily due to **$4.68 million** in net proceeds from the IPO and over-allotment[103](index=103&type=chunk) [Item 3. Quantitative and Qualitative Disclosures About Market Risk](index=26&type=section&id=Item%203.%20QUANTATIVE%20AND%20QUALITATIVE%20DISCLOSURES%20ABOUT%20MARKET%20RISK) The company is a "smaller reporting company" and is therefore not required to provide information for this item - As a "smaller reporting company," the company is exempt from providing quantitative and qualitative disclosures about market risk[108](index=108&type=chunk) [Item 4. Controls and Procedures](index=26&type=section&id=Item%204.%20CONTROLS%20AND%20PROCEDURES) Management concluded disclosure controls were ineffective as of March 31, 2025, due to material weaknesses like lack of documentation and incomplete segregation of duties - The CEO and CFO concluded that as of March 31, 2025, the company's disclosure controls and procedures were not effective at a reasonable assurance level[109](index=109&type=chunk) - Identified control deficiencies include the lack of written documentation for some internal control policies and procedures[112](index=112&type=chunk) - Another deficiency is the lack of complete segregation of duties within accounting functions, though management notes this may not be economically feasible for a company of its size[112](index=112&type=chunk) PART II - OTHER INFORMATION [Item 1. Legal Proceedings](index=27&type=section&id=Item%201.%20LEGAL%20PROCEEDINGS) The company reports that it is not currently a party to any material legal proceedings - The company is not currently a party to any material legal proceedings[114](index=114&type=chunk) [Item 1A. Risk Factors](index=27&type=section&id=Item%201A.%20RISK%20FACTORS) There have been no material changes to the risk factors previously disclosed in the company's Form 10-K for the year ended December 31, 2024 - As of the date of this report, there have been no material changes to the risk factors disclosed in the Form 10-K for the year ended December 31, 2024[115](index=115&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=27&type=section&id=Item%202.%20UNREGISTERED%20SALES%20OF%20EQUITY%20SECURITIES%20AND%20USE%20OF%20PROCEEDS) The company reported no unregistered sales of equity securities during the quarter ended March 31, 2025 - During the quarter ended March 31, 2025, no unregistered sales of equity securities occurred[116](index=116&type=chunk) [Item 6. Exhibits](index=27&type=section&id=Item%206%20EXHIBITS) This section lists exhibits filed with the Form 10-Q, including CEO/CFO certifications and Inline XBRL data files - Exhibits filed include CEO and CFO certifications (31.1, 31.2, 32.1, 32.2) and Inline XBRL documents[120](index=120&type=chunk)

[First Quarter 2025 Results and Business Update](index=1&type=section&id=First%20Quarter%202025%20Results%20and%20Business%20Update) [Management Commentary](index=1&type=section&id=Management%20Commentary) The CEO highlighted the company's strategy to scale its business model into high-growth sectors by leveraging its core strengths in advanced logistics - The company is strategically expanding into new, high-growth markets including GLP-1 pharmaceutical transportation, specialized compounding pharmacy logistics, and premium food packaging services[2](index=2&type=chunk) - A national expansion of emergency preparedness and response operations is underway, with a focus on untapped metropolitan areas and states[2](index=2&type=chunk) - The appointment of Christopher Shields as Senior Vice President of Emergency Preparedness & Response/Government Affairs is intended to accelerate geographic expansion[2](index=2&type=chunk) [Business Highlights](index=1&type=section&id=Business%20Highlights) In early 2025, Callan JMB successfully completed its IPO, raising approximately $5.7 million, strengthened its emergency response division, and secured significant state-level contracts - Completed its Initial Public Offering (IPO) on February 6, 2025, raising gross proceeds of approximately **$5.7 million**[1](index=1&type=chunk)[3](index=3&type=chunk) - Secured a new five-year contract with the Oregon Health Authority and renewed its arrangement with the Texas Department of State Health Services (DSHS) for emergency preparedness[3](index=3&type=chunk) - Appointed former Chicago Department of Public Health Assistant Commissioner, Christopher Shields, as SVP, Emergency Preparedness & Response/Government Affairs[3](index=3&type=chunk) - Launched a comprehensive lease program for vaccine management to reduce the financial burden on government and private organizations[3](index=3&type=chunk) [Financial Results](index=2&type=section&id=Financial%20Results) [Financial Highlights for the First Quarter Ended March 31, 2025](index=2&type=section&id=Financial%20Highlights%20for%20the%20First%20Quarter%20Ended%20March%2031%2C%202025) For the first quarter of 2025, Callan JMB reported revenue of $1.45 million, a decrease attributed to lower demand for emergency preparedness services, and posted a net loss of $1.2 million due to increased SG&A expenses Q1 2025 Financial Summary | Metric | Value | Note | | :--- | :--- | :--- | | **Revenue** | $1.45 million | Decrease due to lower demand for emergency preparedness services | | **Gross Profit** | $0.6 million | - | | **Gross Margin** | 42.5% | - | | **SG&A Expenses** | $1.9 million | Increased due to IPO costs and senior staff hires | | **Operating Loss** | ($1.2) million | - | | **Net Loss** | ($1.2) million | - | [Condensed Consolidated Financial Statements](index=3&type=section&id=Condensed%20Consolidated%20Financial%20Statements) The consolidated financial statements detail the company's financial position and performance, reflecting a strengthened cash position post-IPO, a year-over-year revenue decline, and increased net loss due to higher operating expenses [Condensed Consolidated Balance Sheets](index=3&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) As of March 31, 2025, the company's balance sheet strengthened significantly compared to December 31, 2024, with cash increasing to $5.2 million from $2.1 million, driven by IPO proceeds Balance Sheet Comparison | Account | March 31, 2025 | December 31, 2024 | | :--- | :--- | :--- | | **Cash** | $5,219,929 | $2,097,945 | | **Total Current Assets** | $6,802,104 | $3,319,188 | | **Total Assets** | $8,455,666 | $5,082,549 | | **Total Liabilities** | $1,648,085 | $1,909,191 | | **Total Stockholders' Equity** | $6,807,581 | $3,173,358 | [Condensed Consolidated Statements of Operations](index=4&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) For the three months ended March 31, 2025, revenue decreased to $1.45 million from $1.79 million in the prior-year period, and a sharp increase in SG&A expenses led to a significant widening of the net loss to $1.24 million Statement of Operations (YoY Comparison) | Metric | Three months ended Mar 31, 2025 | Three months ended Mar 31, 2024 | | :--- | :--- | :--- | | **Revenue** | $1,449,377 | $1,790,521 | | **Gross Profit** | $615,940 | $717,583 | | **Selling, general and administrative expenses** | $1,854,316 | $805,042 | | **Operating Loss** | ($1,238,376) | ($87,459) | | **Net Loss** | ($1,240,590) | ($81,133) | | **Net Loss per Share** | ($0.32) | ($0.03) | [Condensed Consolidated Statements of Cash Flows](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) In Q1 2025, net cash used in operating activities was $1.56 million, offset by $4.7 million from financing activities, primarily IPO proceeds, resulting in a net cash increase of $3.1 million Cash Flow Summary (YoY Comparison) | Cash Flow From | For the three months ended March 31, 2025 | For the three months ended March 31, 2024 | | :--- | :--- | :--- | | **Operating Activities** | ($1,561,698) | $6,839 | | **Investing Activities** | ($15,000) | ($44,656) | | **Financing Activities** | $4,698,682 | ($3,460,286) | | **Net Increase (Decrease) in Cash** | $3,121,984 | ($3,498,103) | | **Cash at End of Period** | $5,219,929 | $1,657,517 | - The primary source of cash in Q1 2025 was **$4.68 million** in net proceeds from the company's IPO and overallotment[13](index=13&type=chunk) [Company Information and Disclosures](index=2&type=section&id=Company%20Information%20and%20Disclosures) [About Callan JMB Inc.](index=2&type=section&id=About%20Callan%20JMB%20Inc.) Callan JMB Inc. is an integrative logistics company focused on the healthcare and emergency management sectors, providing specialized services for medical materials - The company specializes in integrative logistics for the healthcare industry and emergency management agencies[5](index=5&type=chunk) - Core services include fulfillment, storage, monitoring, and cold chain logistics for medical materials[5](index=5&type=chunk) [Forward-Looking Statement](index=2&type=section&id=Forward-Looking%20Statement) This press release includes forward-looking statements subject to risks and uncertainties, with actual results potentially differing materially from projections - The report contains forward-looking statements that are subject to risks and uncertainties, and actual results may differ[6](index=6&type=chunk) - Readers are advised to consult the company's Form S-1 Registration Statement for a full list of risk factors[6](index=6&type=chunk)